The phosphoinositide 3-kinase (PI3K)–AKT–mammalian target of rapamycin (mTOR) pathway is frequently altered in several human cancers. Mutational activation of this pathway has been identified to contribute to endocrine resistance in breast cancer and, hence, represents a therapeutic target in this disease. mTOR is a serine and threonine kinase downstream PI3K-AKT signaling, which nucleates 2 cellular complexes, mTORC1 and mTORC2, each with distinct subunits and selectivity for cellular substrates.1 mTORC1 is extremely sensitive to rapamycin, activates S6K, and inactivates 4EBP1, thus promoting anabolic metabolism, protein translation, and nutrient availability. The mTORC2 complex is also activated by PI3K on growth factor stimulation. It is not sensitive to rapamycin and its substrates include Ser473 AKT, SGK1, and PKCα.2
Unni N, Arteaga CL. Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer? JAMA Oncol. Published online August 29, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.2525
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: